Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: medroxyprogesterone Clear all
Terminated Phase 1 Interventional

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women

NCT00044837
View directory record Official record
Conditions
HIV Infections
Interventions
Medroxyprogesterone acetate, Estradiol
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Continuation of Subcutaneous and Intramuscular Depot Medroxyprogesterone Acetate in Post-abortion Patients

NCT05505435
View directory record Official record
Conditions
Contraception
Interventions
Depot-Medroxyprogestereone Acetate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 20, 2026, 4:56 PM EDT
Recruiting Phase 4 Interventional

Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease

NCT06665997
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Interventions
Depot medroxyprogesterone acetate (DMPA)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 20, 2026, 4:56 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 3 Interventional

Heart and Estrogen-Progestin Replacement Study (HERS)

NCT00319566
View directory record Official record
Conditions
Coronary Heart Disease
Interventions
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
2,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2006 · Synced Oct 20, 2026, 4:56 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Estradiol and Fear Extinction in Anorexia Nervosa (AN)

NCT02792153
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Estradiol
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood

NCT02509767
View directory record Official record
Conditions
Contraception
Interventions
Subcutaneous depot medroxyprogesterone acetate
Drug
Lead sponsor
Planned Parenthood Federation of America
Other
Eligibility
15 Years to 44 Years · Female only
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Morristown, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00064025
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery
Other · Drug · Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 20, 2026, 4:56 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives

NCT01750476
View directory record Official record
Conditions
Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
Interventions
Mirena, Oral contraception, Depo-Provera
Drug
Lead sponsor
Thomas Cherpes, DVM, MD
Other
Eligibility
15 Years to 25 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 20, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

NCT00003179
View directory record Official record
Conditions
Endometrial Cancer
Interventions
medroxyprogesterone
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
30
States / cities
Tucson, Arizona • Los Gatos, California • Orange, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2013 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk

NCT02357368
View directory record Official record
Conditions
HIV, Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel intrauterine device (Lng-IUD), ParaGard® T 380A Intrauterine Copper Contraceptive
Drug · Device
Lead sponsor
Lisa Haddad
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 20, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

A Comparison of Continuation Rates for Three Hormonal Contraceptive Methods

NCT00253019
View directory record Official record
Conditions
Contraception
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
321 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 20, 2026, 4:56 PM EDT
Terminated Not applicable Interventional Results available

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

NCT01718444
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension

NCT00420342
View directory record Official record
Conditions
Postmenopause, Hypertension, Pre-Hypertension
Interventions
Drospirenone/17ß-estradiol (Angeliq, BAY86-4891), SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)
Drug
Lead sponsor
Bayer
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Greenbrae, California • San Diego, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate, medroxyprogesterone acetate
Drug
Lead sponsor
Women's Health Care Clinic, Torrance, California
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2014 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Male Hormonal Contraceptive Development-ACY-5

NCT00161447
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 20, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long-Acting Progestin Contraception and the Vaginal Microbiome

NCT02740998
View directory record Official record
Conditions
Sexually Transmitted Infection
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Early Phase 1 Interventional

MPA PK Monitoring Strategy With MMF/FK Based Immunosuppression

NCT00187941
View directory record Official record
Conditions
Transplantation, Renal, Immunosuppression
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Impact of Contraception on Postpartum Weight Loss

NCT02144259
View directory record Official record
Conditions
Weight
Interventions
DMPA immediately postpartum, Implanon immediately postpartum
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

NCT02353247
View directory record Official record
Conditions
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Interventions
Norethindrone acetate
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 20, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

NCT02122198
View directory record Official record
Conditions
Cognitive Impairment, Executive Dysfunction, Endothelial Dysfunction, Cardiovascular Disease
Interventions
Leuprolide acetate, Estradiol, Medroxyprogesterone, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 20, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 20, 2026, 4:56 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Herbal Alternatives for Menopause Symptoms (HALT Study)

NCT00169299
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause
Interventions
Black cohosh, Multibotanical preparation, Multibotanical preparation + dietary soy counseling, Conjugated equine estrogen +/- medroxyprogesterone acetate
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2005 · Synced Oct 20, 2026, 4:56 PM EDT